CV Therapeutics Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Palo Alto CA United States (1990)
Status: Acquired by Gilead Sciences (2009)

Organization Overview

First Clinical Trial
2005
NCT00255307
First Marketed Drug
2006
ranolazine (ranexa)
First NDA Approval
2006
ranolazine (ranexa)
Last Known Activity
2008

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

CV Technologies

Active Ingredients

Marketed Drugs (2)

ranolazine (ranexa) (2006 NDA)

regadenoson (lexiscan) (2008 NDA)

Drugs in Phase 3 Trials (1)

ginseng (3 trials)

Drugs in Phase 2 Trials (2)

panax quinquefolius (1 trial)

ranolazine (ranexa) (1 trial)

Indications

Approved Indications


 

Angina Pectoris

Myocardial Perfusion Imaging

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 3)

Coronary Artery Disease (Phase 2)

Coronary Disease (Phase 2)

Infections (Phase 3)

Ischemia (Phase 2)

Myocardial Ischemia (Phase 2)

Respiratory Tract Infections (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 3